Vanda Pharmaceuticals
VNDA
159 hedge funds and large institutions have $562M invested in Vanda Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 50 reducing their positions, and 43 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 50
1.65% more ownership
Funds ownership: 99.13% → 100.78% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 179 → 159 (-20)
35% less capital invested
Capital invested by funds: $867M → $562M (-$306M)
44% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 43
86% less call options, than puts
Call options by funds: $311K | Put options by funds: $2.27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$21.6M |
| 2 |
SCM
Sio Capital Management
New York
|
+$8.94M |
| 3 |
D.E. Shaw & Co
New York
|
+$6.24M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.49M |
| 5 |
Renaissance Technologies
New York
|
+$4.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.1M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$7.27M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.01M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$4.84M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.24M |
VNDA Hedge Fund Activity: Q1 2020 in Review
159 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2020, worth a combined $562M — down 35% from $867M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of VNDA and 24 opened new positions — a net loss of 19 holders — while 50 trimmed existing stakes and 59 added.
The largest buyer was Armistice Capital, adding an estimated $21.6M. The largest seller was Invesco, cutting an estimated $12.1M.
- 159 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2020, down from 179 in Q4 2019.
- Funds reported $562M of Vanda Pharmaceuticals stock for Q1 2020, down 35% quarter-over-quarter.
- 24 funds opened new Vanda Pharmaceuticals positions in Q1 2020 and 43 closed out, a net change of -19 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2020 was Armistice Capital, an estimated $21.6M added.
- The largest Vanda Pharmaceuticals seller in Q1 2020 was Invesco, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2020.